David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML

Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.